Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yangxin Shengmai Granules versus Yixinshu Tablets for stable angina in coronary heart disease
ChiCTR2400084236Phase 4Recruiting
- Sponsor
- Guang'anmen Hospital
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Yangxin Shengmai in coronary arteriosclerosis and stable angina (2 arms), sponsored by Guang'anmen Hospital. Primary endpoint: Seattle Angina Questionnaire. Started May 2024; status: recruiting.
02
Drugs
Yangxin Shengmai
03
Conditions
coronary arteriosclerosisstable angina
Beyond the preview
Go deeper on ChiCTR2400084236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084236.